Genomics Data Analysis System Speeds Drug R&D
|
By LabMedica International staff writers Posted on 25 Nov 2009 |
A new genomics data-analysis system was designed for advancing life science research, discovery, and development.
Tibco Software, Inc. (Palo Alto,CA, USA), together with Integromics (Madrid, MA, USA), a provider of software systems for data management and data analysis in genomics, proteomics, and drug discovery, reported that Integromics Biomarker Discovery 2.0 for Tibco Spotfire is a new solution that sets the standard for advanced methods of data access, normalization, pattern detection, treatment comparison, and functional analysis for scientists analyzing genomic expression data. This powerful platform plays a pivotal role in leveraging the considerable investment in gene expression technologies that the pharmaceutical and biotechnology industries have made in the last 10 years. Gaining new insights into disease biology, mechanism of action and drug safety will be a key differentiator in early drug discovery.
The scientific and workflow knowledge of Integromics--combined with the adaptability and ease of use of the Tibco Spotfire enterprise analytics platform--provides pharmaceutical, biotechnology, and academic research groups a powerful genomic data analysis environment that rapidly finds and categorizes complex patterns. With interactive analysis and high-impact visualization capabilities, Integromics Biomarker Discovery 2.0 for Tibco Spotfire quickly reveals insights and unexpected relationships in genomics data. This allows researchers and scientists to examine the expression and annotation dimensions of their data and perform a variety of numerical analyses--all in one application. Pharmaceutical companies can also use Tibco Spotfire as a flexible analytics platform to combine and analyze new types of data to pursue more quickly hypotheses and research strategies.
"Having developed microarray analytics for over five years and benefited from a successful partnership with Spotfire for several years now, we are confident that this combined solution will provide researchers with a powerful environment to accelerate discovery and provide accurate, up-to-date analytics from a single reliable source,” said Imad Yassin, global commercial director, Integromics. "With this set of tools, life-science researchers can ask and answer new questions and create an advanced problem solving environment.”
"Genomics research typically involves measuring the activity of thousands of genes in many different treatments or conditions, and combining that information with other data to uncover new insight into the biology of disease and treatment,” said Mark Lorion, vice president of marketing, Tibco Spotfire. "This solution helps researchers and scientists address one of the industry's long-standing challenges of creating knowledge from mass data by easily integrating multiple data sources and transforming data into an interactive decision-making asset.”
Integromics develops information technology (IT) solutions for life sciences (genomics and proteomics) in two strategic areas: data management/integration and intelligent data analysis. Over the years, the company has developed a network of collaborations and partnerships with leading industry and academic organizations to provide complete technological solutions that enable scientists to make new discoveries from their research data. Integromics operates globally in Asia Pacific, Europe, and the United States.
Tibco Software is a leading provider of enterprise analytics software for next generation business intelligence. Distinguished by its speed to insight and adaptability to specific business challenges, Spotfire rapidly reveals unseen threats and new opportunities, creating significant economic value.
Related Links:
Tibco Software
Integromics
Tibco Software, Inc. (Palo Alto,CA, USA), together with Integromics (Madrid, MA, USA), a provider of software systems for data management and data analysis in genomics, proteomics, and drug discovery, reported that Integromics Biomarker Discovery 2.0 for Tibco Spotfire is a new solution that sets the standard for advanced methods of data access, normalization, pattern detection, treatment comparison, and functional analysis for scientists analyzing genomic expression data. This powerful platform plays a pivotal role in leveraging the considerable investment in gene expression technologies that the pharmaceutical and biotechnology industries have made in the last 10 years. Gaining new insights into disease biology, mechanism of action and drug safety will be a key differentiator in early drug discovery.
The scientific and workflow knowledge of Integromics--combined with the adaptability and ease of use of the Tibco Spotfire enterprise analytics platform--provides pharmaceutical, biotechnology, and academic research groups a powerful genomic data analysis environment that rapidly finds and categorizes complex patterns. With interactive analysis and high-impact visualization capabilities, Integromics Biomarker Discovery 2.0 for Tibco Spotfire quickly reveals insights and unexpected relationships in genomics data. This allows researchers and scientists to examine the expression and annotation dimensions of their data and perform a variety of numerical analyses--all in one application. Pharmaceutical companies can also use Tibco Spotfire as a flexible analytics platform to combine and analyze new types of data to pursue more quickly hypotheses and research strategies.
"Having developed microarray analytics for over five years and benefited from a successful partnership with Spotfire for several years now, we are confident that this combined solution will provide researchers with a powerful environment to accelerate discovery and provide accurate, up-to-date analytics from a single reliable source,” said Imad Yassin, global commercial director, Integromics. "With this set of tools, life-science researchers can ask and answer new questions and create an advanced problem solving environment.”
"Genomics research typically involves measuring the activity of thousands of genes in many different treatments or conditions, and combining that information with other data to uncover new insight into the biology of disease and treatment,” said Mark Lorion, vice president of marketing, Tibco Spotfire. "This solution helps researchers and scientists address one of the industry's long-standing challenges of creating knowledge from mass data by easily integrating multiple data sources and transforming data into an interactive decision-making asset.”
Integromics develops information technology (IT) solutions for life sciences (genomics and proteomics) in two strategic areas: data management/integration and intelligent data analysis. Over the years, the company has developed a network of collaborations and partnerships with leading industry and academic organizations to provide complete technological solutions that enable scientists to make new discoveries from their research data. Integromics operates globally in Asia Pacific, Europe, and the United States.
Tibco Software is a leading provider of enterprise analytics software for next generation business intelligence. Distinguished by its speed to insight and adaptability to specific business challenges, Spotfire rapidly reveals unseen threats and new opportunities, creating significant economic value.
Related Links:
Tibco Software
Integromics
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







